Indivior PLC (INDV)
NASDAQ: INDV · Real-Time Price · USD
13.95
+0.26 (1.90%)
At close: Jun 27, 2025, 4:00 PM
13.26
-0.69 (-4.95%)
After-hours: Jun 27, 2025, 6:18 PM EDT
Indivior Revenue
Indivior had revenue of $266.00M in the quarter ending March 31, 2025, a decrease of -6.34%. This brings the company's revenue in the last twelve months to $1.17B, up 4.09% year-over-year. In the year 2024, Indivior had annual revenue of $1.19B with 8.69% growth.
Revenue (ttm)
$1.17B
Revenue Growth
+4.09%
P/S Ratio
1.49
Revenue / Employee
$1,113,225
Employees
1,051
Market Cap
1.75B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.19B | 95.00M | 8.69% |
| Dec 31, 2023 | 1.09B | 192.00M | 21.31% |
| Dec 31, 2022 | 901.00M | 110.00M | 13.91% |
| Dec 31, 2021 | 791.00M | 144.00M | 22.26% |
| Dec 31, 2020 | 647.00M | -138.00M | -17.58% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.22B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
INDV News
- 3 days ago - Indivior Appoints Tony Kingsley to the Board of Directors - PRNewsWire
- 9 days ago - Indivior Presents New Data at CPDD Demonstrating that High Buprenorphine Exposure May Improve Treatment Outcomes in High Fentanyl Users - PRNewsWire
- 26 days ago - Indivior to delist from London Stock Exchange, maintain Nasdaq listing - Reuters
- 26 days ago - Indivior Announces Intention to Cancel Secondary Listing on London Stock Exchange; Primary Listing on Nasdaq to be Maintained - PRNewsWire
- 4 weeks ago - Indivior Announces Patrick Barry as Chief Commercial Officer - PRNewsWire
- 6 weeks ago - Indivior to Participate in Upcoming Investor Events - PRNewsWire
- 2 months ago - New Study Highlights Monthly SUBLOCADE® as a Potential Treatment Option for Opioid Use Disorder During and After Pregnancy - PRNewsWire
- 2 months ago - Indivior: Trying To Break Addiction - Seeking Alpha